Drugs / Asiaticoside
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07241533 | Dec 2025 → Nov 2026 expected | obesity disorder | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06566508 Comparator | Nov 2023 → Jun 2024 overdue | — | Mansoura University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Asiaticoside | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06566508 ↗ |
| Modality | Small molecule | — CHEMBL1789965 ↗ |
| Route | Other | “Asiaticoside Intracanal medication” NCT06566508 ↗ |